Spotlight Growth
No Result
View All Result
Sunday, March 26, 2023
  • Home
  • News
    • Bio/Med/Pharma
    • Cannabis
    • Commodities
    • Consumer Goods
    • Crowdfunding
    • Cryptocurrency
    • Crypto Cheat Sheets
    • Earnings
    • Entertainment
    • Financials
    • Market News
    • Opinion
    • Politics
    • Technology
    • Venture Capital/Private Equity (VC/PE)
  • Video
  • Stock and Crypto Screener
  • Home
  • News
    • Bio/Med/Pharma
    • Cannabis
    • Commodities
    • Consumer Goods
    • Crowdfunding
    • Cryptocurrency
    • Crypto Cheat Sheets
    • Earnings
    • Entertainment
    • Financials
    • Market News
    • Opinion
    • Politics
    • Technology
    • Venture Capital/Private Equity (VC/PE)
  • Video
  • Stock and Crypto Screener
No Result
View All Result
No Result
View All Result
Home Bio/Med/Pharma

Aptorum Group (NASDAQ: APM) Granted FDA Orphan Drug Designation for SACT-1 and Treatment of Neuroblastoma

by admin
January 20, 2022
in Bio/Med/Pharma
0
Aptorum Group NASDAQ APM SACT1 FDA Orphan Drug Spotlight Growth

Aptorum Group NASDAQ APM SACT1 FDA Orphan Drug Spotlight Growth

Aptorum Group Limited (NASDAQ: APM) is engaged as a clinical-stage biopharmaceutical company, which is focused on the research, development and commercialization of novel treatments for unmet medical needs; particularly in oncology. Shares of the biopharma are surging 30% through early trading on Thursday, January 20, 2022. Over the past three months, Aptorum Group has seen average daily volume of 127,520 shares. However, volume of 72.83 million shares or dollar volume of around $119.44 million, has already exchanged hands through early trading on Thursday.

Shares of Aptorum Group are surging after the company announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to the company’s SACT-1 candidate, a repurposed small molecule compound for the treatment of Neuroblastoma. The company says they are planning to file an Investigational New Drug (IND) Application to begin Phase 1b/2a clinical trials this year.

SACT-1 is an orally-administered drug that has shown in preclinical studies to improve killing of tumor cells, as well as suppress MYCN expression. The drug candidate is meant to be used in combination with standard-of-care chemotherapy.

Mr. Darren Lui, President and Executive Director of Aptorum Group says, “The granting of orphan drug designation for SACT-1 for the treatment of neuroblastoma is another important step forward in the development of our drug candidate and reflects both the FDA’s and Aptorum’s commitment to addressing the unmet clinical needs of patients with neuroblastoma.” Further to our recently announced completion of Phase 1 clinical trial and patent grant for SACT-1, we are currently focusing on our IND preparation for entering into the exciting Phase 1b/2a clinical trials for SACT-1 in the United States.”

Disclosure: Neither Spotlight Growth nor its officers have any position or relationship with any companies mentioned in this article, but may choose to initiate a position at any time. No payment was made to create this article. This article should not be taken as a solicitation or recommendation to buy or sell any securities. Please conduct your own research and consult your financial advisor to determine your risk tolerance and investment path. We are not licensed brokers or investment advisors.

Tags: APMAPM stockAptorum Groupbiopharmabiopharmaceuticalsbiotechcommon stockemerging growthinvestinginvesting newsinvestmentmanufacturingmedicalmedical stocksmicrocap stocksNASDAQnewsoncologypharmaceuticalspublic companyRobinhoodrobinhood stockssalesservicessmall cap companiessmall cap stockssmall capsSpotlight GrowthSpotlight Growth Stocksstock market newsstocks to watchtradingtreatment
  • Trending
  • Comments
  • Latest
Asure Software NASDAQ ASUR Human Capital Management HCM Industry Spotlight Growth

Asure Software (NASDAQ: ASUR) is Expanding to Meet the Rising Demand for Human Capital Management Software

September 27, 2022
OLB Group NASDAQ OLB Cuentas NASDAQ CUEN Partnership Fintech Spotlight Growth

OLB Group (NASDAQ: OLB) and Cuentas (NASDAQ: CUEN) Team Up to Bring Fintech Solutions to Over 32,000 Bodegas Across the United States

October 6, 2022
Siyata Mobile NASDAQ SYTA SYTAW SD7 VK7 Purchase Orders Spotlight Growth

New Purchase Orders for SD7 Rugged Device, VK7, and Other Accessories Boost Siyata Mobile’s Outlook (NASDAQ: SYTA)

December 14, 2021
Telcoin TEL Crypto Spotlight Growth

Telcoin (TEL) Quietly Leads a Crypto Remittance Revolution

June 15, 2021
Cybersecurity Stocks Coming Into Focus Amid High-Profile Attacks

Cybersecurity Stocks Coming Into Focus Amid High-Profile Attacks

0
Safe-T SFET NASDAQ UN Presentation

Safe-T (NASDAQ: SFET) Has Been Selected to Present at the United Nations’ Office of Information and Communications Technology Event

0
Safe-T Group SFET Q4 FY 2020 Financial Results

Safe-T Group (NASDAQ: SFET) Reports Fourth Quarter and Full Year 2020 Financial Results

0
Safe-T Group NASDAQ SFET FY 2020 Prelim

Safe-T Group Ltd. (NASDAQ: SFET) Estimates Record-High Annual Revenues of Approximately $4.9 Million Representing ~50% Growth YoY 2020

0
Is U.S. Government Trying to Ban Crypto Spotlight Growth

Is The U.S. Government Trying to Ban Crypto?

March 23, 2023
Bioadaptives OTC Pink BDPT LOI World Wellness Health and Wellness Spotlight Growth

Bioadaptives (OTC Pink: BDPT) Signs LOI with World Wellness, LLC to Develop New Health and Wellness Products

March 23, 2023
JanOne NASDAQ JAN Sells ARCA Recycling Business Focus on Biopharma Spotlight Growth

JanOne (NASDAQ: JAN) Sells ARCA Recycling Business to VM7, Will Focus on Budding Biopharmaceuticals Business

March 22, 2023
89bio NASDAQ ETNB Phase 2b ENLIVEN Trial Pegozafermin NASH Spotlight Growth

89bio (NASDAQ: ETNB) Reports Phase 2b ENLIVEN Trial of Pegozafermin Achieved Primary Endpoints For Treatment of Nonalcoholic Steatohepatitis (NASH)

March 22, 2023

Recent News

Is U.S. Government Trying to Ban Crypto Spotlight Growth

Is The U.S. Government Trying to Ban Crypto?

March 23, 2023
Bioadaptives OTC Pink BDPT LOI World Wellness Health and Wellness Spotlight Growth

Bioadaptives (OTC Pink: BDPT) Signs LOI with World Wellness, LLC to Develop New Health and Wellness Products

March 23, 2023

Categories

  • Bio/Med/Pharma
  • Cannabis
  • Commodities
  • Consumer Goods
  • Crowdfunding
  • Crypto Cheat Sheets
  • Cryptocurrency
  • Earnings
  • Education
  • Entertainment
  • Financials
  • Market News
  • Opinion
  • Politics
  • Real Estate
  • Split Watch
  • Sponsored
  • Store
  • Technology
  • Uncategorized
  • Venture Capital/Private Equity (VC/PE)

Site Navigation

  • Disclosures
  • Terms Of Service
  • Privacy Policy
  • Contact Us

Copyright © 2017-2022 Spotlight Growth. All Right Reserved. Designed by Cool Cat Interactive.

No Result
View All Result
  • Home
  • News
    • Bio/Med/Pharma
    • Cannabis
    • Commodities
    • Consumer Goods
    • Crowdfunding
    • Cryptocurrency
    • Crypto Cheat Sheets
    • Earnings
    • Entertainment
    • Financials
    • Market News
    • Opinion
    • Politics
    • Technology
    • Venture Capital/Private Equity (VC/PE)
  • Video
  • Stock and Crypto Screener

Copyright © 2017-2022 Spotlight Growth. All Right Reserved. Designed by Cool Cat Interactive.

Newsletter Signup

Subscribe to our weekly newsletter below and never miss the latest small/micro-cap analysis and investment news from Spotlight Growth.

Enter your email address

Thanks, I’m not interested